<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01040143</url>
  </required_header>
  <id_info>
    <org_study_id>PneuCaSt</org_study_id>
    <nct_id>NCT01040143</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci</brief_title>
  <acronym>Pneucast</acronym>
  <official_title>A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Public Health England</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Public Health England</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study taking swabs from the back of the nose (nasopharynx) to look at carriage of
      pneumococci.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of pneumococci in nasopharyngeal swabs</measure>
  </primary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Pneumococcal Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Community samples taken within the home of eligible subjects.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Born in a cohort eligible for routine or catch up pneumococcal conjugate vaccination
             (i.e. date of birth since 4th September 2004) or a family member where a child is
             eligible and has been enrolled

          -  Written informed consent given by the subject's parent/ legal guardian as well as
             assent from the child after the nature of the study has been explained to them or

          -  Written informed consent given by the subject after the nature of the study has been
             explained to them

        Exclusion Criteria:

          -  Moderate to severe disability.

          -  Cerebral palsy, syndromes and neurological disorders affecting swallowing.

          -  Ear Nose and Throat disorders affecting the anatomy of the ear,i.e.malformed ears.

          -  Confirmed or suspected immunodeficiency (congenital or acquired).

          -  On immunosuppressive therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Health Protection Agency</name>
      <address>
        <city>Stevenage</city>
        <state>Hertfordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Protection Agency</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Protection Agency</name>
      <address>
        <city>London</city>
        <zip>NW9 5HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/24657717</url>
    <description>Published study results</description>
  </link>
  <results_reference>
    <citation>van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MP, Harrison TG, Ladhani SN, Miller E. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014 Jul 23;32(34):4349-55. doi: 10.1016/j.vaccine.2014.03.017. Epub 2014 Mar 21.</citation>
    <PMID>24657717</PMID>
  </results_reference>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>December 28, 2009</study_first_submitted>
  <study_first_submitted_qc>December 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2009</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <name_title>Professor Elizabeth Miller</name_title>
    <organization>Health Protection Agency</organization>
  </responsible_party>
  <keyword>Pneumococci</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

